Evidence map›Paper›PMID 24782985›Full record

ReviewFrontiers in oncology2014

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.

Zong Sheng Guo, Zuqiang Liu, David L Bartlett

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers.

0numbers the graph read from it
0cells of the map it votes in
190citing papers in PubMed
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

190 citing papers in PubMed, 278 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Specific inhibitor to KRASJournal for immunotherapy of cancer · 2025
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

130 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zong Sheng GuoDepartment of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
Zuqiang LiuDepartment of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
David L BartlettDepartment of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA.
UPMC Hillman Cancer Center · US

Funding

Type-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-CelP01CA132714 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KALINSKI, PAWEL · 2009 to 2013
$6.8M
Improving Vaccinia for Peritoneal Tumors: Enhanced Distribution & Immune EvasionR01CA155925 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BARTLETT, DAVID L · 2011 to 2015
$1.5M
NCI NIH HHS P01 CA132714NCI NIH HHS R01 CA155925
6 · The paper itself

Abstract

Oncolytic viruses (OVs) are novel immunotherapeutic agents whose anticancer effects come from both oncolysis and elicited antitumor immunity. OVs induce mostly immunogenic cancer cell death (ICD), including immunogenic apoptosis, necrosis/necroptosis, pyroptosis, and autophagic cell death, leading to exposure of calreticulin and heat-shock proteins to the cell surface, and/or released ATP, high-mobility group box 1, uric acid, and other damage-associated molecular patterns as well as pathogen-associated molecular patterns as danger signals, along with tumor-associated antigens, to activate dendritic cells and elicit adaptive antitumor immunity. Dying the right way may greatly potentiate adaptive antitumor immunity. The mode of cancer cell death may be modulated by individual OVs and cancer cells as they often encode and express genes that inhibit/promote apoptosis, necroptosis, or autophagic cell death. We can genetically engineer OVs with death-pathway-modulating genes and thus skew the infected cancer cells toward certain death pathways for the enhanced immunogenicity. Strategies combining with some standard therapeutic regimens may also change the immunological consequence of cancer cell death. In this review, we discuss recent advances in our understanding of danger signals, modes of cancer cell death induced by OVs, the induced danger signals and functions in eliciting subsequent antitumor immunity. We also discuss potential combination strategies to target cells into specific modes of ICD and enhance cancer immunogenicity, including blockade of immune checkpoints, in order to break immune tolerance, improve antitumor immunity, and thus the overall therapeutic efficacy.

Indexed as

antitumor immunityautophagycross-presentationDAMPsimmune toleranceimmunogenic cancer cell deathPAMPtumor-associated antigen

Identifiers

PMID24782985
PMCPMC3989763
OpenAlexW1967262248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.